Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ulrike Burk is active.

Publication


Featured researches published by Ulrike Burk.


Journal of Biological Chemistry | 2007

Inhibition of GSK3 promotes replication and survival of pancreatic beta cells.

Rainer Mussmann; Marcus Geese; Friedrich Harder; Simone Kegel; Uwe Andag; Alexander Lomow; Ulrike Burk; Daria Onichtchouk; Cord Dohrmann; Matthias Austen

Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible. A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control. Here we report that the inactivation of GSK3 by small molecule inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells. Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concentrations of glucose and the saturated fatty acid palmitate on INS-1E cells. Furthermore, treatment of isolated rat islets with structurally diverse small molecule GSK3 inhibitors increases the rate beta cell replication by 2–3-fold relative to controls. We propose that GSK3 is a regulator of beta cell replication and survival. Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.


Journal of Medicinal Chemistry | 2008

9-Cyano-1-azapaullone (Cazpaullone), a Glycogen Synthase Kinase-3 (GSK-3) Inhibitor Activating Pancreatic β Cell Protection and Replication

Hendrik Stukenbrock; Rainer Mussmann; Marcus Geese; Yoan Ferandin; Olivier Lozach; Thomas Lemcke; Simone Kegel; Alexander Lomow; Ulrike Burk; Cord Dohrmann; Laurent Meijer; Matthias Austen; Conrad Kunick

Recently, the serine/threonine kinase glycogen synthase kinase-3 (GSK-3) emerged as a regulator of pancreatic beta cell growth and survival. On the basis of the previous observation that GSK-3 inhibitors like 1-azakenpaullone promote beta cell protection and replication, paullone derivatives were synthesized including 1-aza-, 2-aza-, and 12-oxapaullone scaffolds. In enzymatic assays distinct 1-azapaullones were found to exhibit selective GSK-3 inhibitory activity. Within the series of 1-azapaullones, three derivatives stimulated INS-1E beta cell replication and protected INS-1E cells against glucolipotoxicity induced cell death. Cazpaullone (9-cyano-1-azapaullone), the most active compound in the protection assays, also stimulated the replication of primary beta cells in isolated rat islets. Furthermore, cazpaullone showed a pronounced transient stimulation of the mRNA expression of the beta cell transcription factor Pax4, an important regulator of beta cell development and growth. These features distinguish cazpaullone as a unique starting point for the development of beta cell regenerative agents which might be useful in the treatment of diabetes.


Archive | 2005

USE OF A TIMP-2 SECRETED PROTEIN PRODUCT FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME

Daria Onichtchouk; Ulrike Burk; Ursula Hoffmann


Archive | 2004

Method for Preventing and Treating Diabetes Using Neurturin

Matthias Austen; Ulrike Burk


Archive | 2006

Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders

Rainer Mussmann; Conrad Kunick; Hendrik Stukenbrock; Marcus Geese; Simone Kegel; Ulrike Burk


Archive | 2011

Method for treating diabetes using neurturin

Matthias Austen; Ulrike Burk


Archive | 2004

Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome

Daria Onichtchouk; Karsten Eulenberg; Tri Nguyen; Ulrike Burk


Archive | 2006

Use of gip and/or vitamin d3 analogues thereof for enhancing stem or progenitor cell differentiation into insulin producing cells

Matthias Austen; Ulrike Burk


Archive | 2013

Method for promoting regeneration of pancreatic beta-cells by administering neurturin

Matthias Austen; Ulrike Burk


Archive | 2005

Utilisation d'un produit proteique timp-2 secrete pour la prevention et le traitement d'affections du pancreas, de l'obesite et/ou du syndrome metabolique

Daria Onichtchouk; Ulrike Burk; Ursula Hoffmann

Collaboration


Dive into the Ulrike Burk's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Conrad Kunick

Braunschweig University of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rainer Mussmann

Netherlands Cancer Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Laurent Meijer

Centre national de la recherche scientifique

View shared research outputs
Researchain Logo
Decentralizing Knowledge